SHINE - Stroke Hyperglycemia Insulin Network Effort 

Registered with NCT01369069

NIH Project Number: 5U01NS069498-05

Status: Complete

Congratulations SHINE team on the completion of SHINE enrollment with 1151 subjects!

Dr. Karen C. Johnston presented the primary results of the SHINE trial on behalf of the entire SHINE team on February 6, 2019 during the ISC Plenary Session in Honolulu, Hawaii. Her slide presentation can be viewed here.

FINDINGS: See the full publication from JAMA below: 

This was a multicenter, prospective, randomized, controlled trial, with blinded outcomes. It aimed to determine the efficacy and provide further safety data on the use of insulin infusion therapy for glucose control in hyperglycemic acute ischemic stroke patients. Treatment with insulin infusion was given within 12 hours of symptom onset. The primary outcome assessed at 90 days was the difference in favorable outcome measured by the modified Rankin Scale score in the insulin infusion group compared to the control group. The rates of symptomatic hypoglycemia with prolonged neurological worsening as well as asymptomatic hypoglycemia was assessed. The secondary outcomes assessed additional neurological and functional outcomes. This highly collaborative research program is nearly guaranteed to advance the field of stroke care.

Trial Overview